UK-based Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA ...

Among significant news last week, Halozyme Therapeutics struck a license agreement for its INCA033989 with fellow USA-based ...

The US unit of Japan’s Otsuka (TYO: 4578) has been granted US Food and Drug Administration (FDA) approval for Simtriyo (centanafadine), a once-daily extended-release capsule for the treatment of ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) today announced recommendations for the approval of ...

French pharma major Sanofi (Euronext: SAN) today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD).

US pharma major Johnson & Johnson has reported positive top-line Phase III data showing that a dual bispecific antibody ...

Spanish medical dermatology company Almirall (BME: ALM) has reported first-half 2026 net sales of 602.7 million euros ($687.1 ...

A commercial-stage Chinese biopharmaceutical company pursuing BTK and TYK2 inhibition across oncology and autoimmune disease, ...

French ophthalmology specialist Théa has entered into a long-term manufacturing partnership with French CDMO Unither Pharmaceuticals to build a dedicated sterile eye care production facility in the ...

Roche (ROG: SIX) today posted first-half 2026 financial results that beat analysts’ expectations, pushing the Swiss pharma major’s shares up 3.2% to 343.00 francs. Group sales for the first half were ...

US RNA medicines company Arrowhead Pharmaceuticals (Nasdaq: ARWR) saw its shares rise about 19% after reporting positive top-line results from two pivotal Phase III studies of plozasiran in severe ...

A young California start-up wants to do for drug development what enterprise software did for accounting and sales: put the ...